Literature DB >> 16563622

Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray.

Baohong Jiang1, Yufeng Shi, Haohong Li, Lin Kang, Lan Ma.   

Abstract

Beta-arrestin 2 plays important physiological roles in regulating the function of the mu opioid receptor (muOR) in vivo. Periaqueductal gray (PAG) is a potential structure where morphine produces its antinociception, but it is unclear whether beta-arrestin 2 plays its regulatory effect on morphine at PAG. In the present study beta-arrestin 2 overexpression was induced by adenovirus at PAG of rats. Morphine was administrated in these rats through PAG microinjection and systemic administration. The antinociceptive effects of morphine were abolished in rats received microinjection of morphine at PAG and partially attenuated in rats received systemic administration of morphine. These findings support the notion that PAG is an important site where beta-arrestin 2 plays its regulatory effects on morphine analgesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563622     DOI: 10.1016/j.neulet.2006.02.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014

4.  Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.

Authors:  Dominique D Pierroz; Anna Rufo; Estelle N Bianchi; Vaida Glatt; Mattia Capulli; Nadia Rucci; Fanny Cavat; René Rizzoli; Anna Teti; Mary L Bouxsein; Serge L Ferrari
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

Review 5.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 6.  Targeting G protein coupled receptor-related pathways as emerging molecular therapies.

Authors:  Abdelaziz Ghanemi
Journal:  Saudi Pharm J       Date:  2013-08-13       Impact factor: 4.330

7.  miR-365 targets β-arrestin 2 to reverse morphine tolerance in rats.

Authors:  Jian Wang; Wei Xu; Tao Zhong; Zongbin Song; Yu Zou; Zhuofeng Ding; Qulian Guo; Xinzhong Dong; Wangyuan Zou
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

8.  Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study.

Authors:  Agata Korlatowicz; Maciej Kuśmider; Marta Szlachta; Paulina Pabian; Joanna Solich; Marta Dziedzicka-Wasylewska; Agata Faron-Górecka
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

9.  Improvement of morphine-mediated analgesia by inhibition of β-arrestin2 expression in mice periaqueductal gray matter.

Authors:  Yuting Li; Xing Liu; Chang Liu; Jiuhong Kang; Jingyu Yang; Gang Pei; Chunfu Wu
Journal:  Int J Mol Sci       Date:  2009-03-05       Impact factor: 5.923

10.  Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice.

Authors:  Henning Ohnesorge; Zhiying Feng; Karina Zitta; Markus Steinfath; Martin Albrecht; Berthold Bein
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.